CEO Today - March 2023

www.ceotodaymagazine.com 23 dramatically reduce the risk of wound and surgical site infection. 3. It delivers this antimicrobial impact without the release of high-volume ionic silver. 4. It is priced on par with silver products. It is 510(k) cleared with broad indications for both prescription and over-thecounter uses. This affords us leverage to follow evolving market dynamics and expand into new sites of service and sales channels. We’re proud to have treated over one million wounds to-date, and are currently selling in 11 countries under the brand names Procellera® and JumpStart® Antimicrobial Wound Dressings, powered by V.Dox® Technology. In addition to a single-layer and composite dressings, Vomaris also has the OrthoEliteTM product line, with shapes and sizes dedicated to the unique needs of orthopaedic surgeons and their patients. New product development efforts are focused in four key areas where infection control and healing remain a significant challenge: Orthopedic Surgery, Sports Medicine and Trauma (with a licensing and distribution agreement with Arthrex, Inc.) burns, chronic wounds, and Hidradenitis Suppurativa (a chronic inflammatory skin condition). What are your biggest goals and aspirations for the future of Vomaris? It’s time to elevate the standard of care.We at Vomaris have the technology, scientific and clinical evidence, and financial strength from Franklin Mountain to enable us to make a significant difference for patients suffering from acute and chronic wounds. We believe the future of infection control and wound healing is electric. Email: mike.nagel@vomaris.com Q Q Q Mike Nagel “6.7million Americans have chronic wounds. ”

RkJQdWJsaXNoZXIy Mjk3Mzkz